**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**



CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
  SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 16, 2013

**PFIZER INC.**
  (Exact name of registrant as specified in its charter)

|**Delaware**                                                                                       | **1-3619**               | **13-5315170**                      
|-------------------------------------------------------------------------------------------------- | ------------------------ | ------------------------------------
|(State or other Jurisdiction of incorporation)                                                     | (Commission File Number) | (I.R.S. Employer Identification No.)
|**235 East 42nd Street 
          New York, New York**(Address of principal executive offices)**** |                          | **10017**
        (Zip Code)        

> Registrant's telephone number, including area code:(212) 733-2323 ****Not Applicable	
>       (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended
  to simultaneously satisfy the obligation of the registrant under any of the
  following provisions:

[   ] Written communication pursuant to Rule 425 under the Securities
  Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange
  Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))



|Item 5.03                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | **Amendments to Articles of  Incorporation or Bylaws; Change in Fiscal Year.**
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------
|On December 16, 2013, the Board of  Directors of Pfizer Inc. (the “Company”) approved certain amendments to the  Company's By-laws, as follows:
    Article I,       Section 8 (“List of Stockholders Entitled to Vote”) was amended to provide       that the list of stockholders entitled to vote at a meeting of       stockholders be kept (i) at the Company’s headquarters or (ii) on a       reasonably accessible electronic network, consistent with requirements of       the Delaware General Corporation Law.
      Article I,       Section 13 (“Notice of Stockholder Proposal”) was amended to clarify that,       to be in proper written form, a proponent’s notice must include the text       of any resolutions proposed for consideration and, if such business       includes a proposal to amend the By-laws, the text of the proposed       amendment.
      Article III,       Section 1 (“Election; Term of Office; Appointments”) was amended to delegate       authority to the Corporate Secretary or any elected corporate officer acting       with the Corporate Secretary to appoint Assistant Officers.
      Article V,       Section 2 (“Prepayment of Expenses”) was amended to delegate authority to       the General Counsel to approve advancement of litigation expenses for       non-officer colleagues, as well as former directors and officers.
      In addition to the changes described above, the  amended By-laws include revisions (1) to enhance clarity, including by removing repetitive or inconsistent passages and (2)  which constitute technical corrections and non-substantive changes.The preceding is qualified  in its entirety by reference to the Company’s amended By-laws, which are  attached hereto as Exhibit 3.1 and are incorporated herein by reference.



|**Item 9.01** | **Financial Statements and Exhibits.** | 
|------------- | -------------------------------------- | 

|(d) Exhibits |                                                        | 
|------------ | ------------------------------------------------------ | 
|             |                                                        | 
|Exhibit No.  | Description                                            | 
|Exhibit 3.1  | Pfizer Inc. By-laws, as  amended on December 16, 2013. | 
|             |                                                        | 



**SIGNATURE**

Under the requirements of the Securities Exchange Act of 1934, the registrant
  has caused this report to be signed on its behalf by the authorized undersigned.

|                         |  | PFIZER INC.                                    
|------------------------ |  | -----------------------------------------------
|                         |  |                                                
|                         |  | By: /s/  Matthew Lepore
         Matthew Lepore
|                         |  | Title: Vice President and Corporate Secretary  
|Dated: December 19, 2013 |  |                                                



> EXHIBIT INDEX

|Exhibit No. | Description                                           
|----------- | ------------------------------------------------------
|Exhibit 3.1 | Pfizer Inc. By-laws, as  amended on December 16, 2013.